ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.

Auteurs

Soumoy L, Genbauffe A, Mouchart L, Sperone A, Trelcat A, Mukeba-Harchies L, Wells M, Blankert B, Najem A, Ghanem G, Saussez S, Journe F

  • Date de publication

    January 2024

  • Type

    Article

  • Review

    Cancer Cell Int

  • Researcher's name

    NAJEM Ahmad

  • Hôpital

    Institut Jules Bordet

  • Service

    Laboratoire d'anatomie pathologie, Laboratoire d'oncologie et de chirurgie expérimentale

  • PMID

    38178183

  • DOI

    10.1186/s12935-023-03196-y